ALLO · US market
Allogene Therapeutics Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$532.06mFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$165.49m
- Latest-quarter run-rate earnings
- -US$170.71m
- Latest fiscal-year earnings
- -US$190.89m
- Trailing revenue
- US$4.64m
- Latest-quarter run-rate revenue
- US$18.56m
- Latest fiscal-year revenue
- Unavailable
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- QQQS · Invesco NASDAQ Future Gen 200 ETF0.32% weight · Holdings dated 31 May 2026
- XBI · State Street SPDR S&P Biotech ETF0.23% weight · Holdings dated 21 August 2026
- TMED · T. Rowe Price Health Care ETF0.21% weight · Holdings dated 30 June 2026
- NOSGX · Northern Small Cap Value Fund0.19% weight · Holdings dated 30 June 2026
- KOMP · State Street SPDR S&P Kensho New Economies Composite ETF0.11% weight · Holdings dated 19 August 2026
- VSTCX · Vanguard Strategic Small-Cap Equity Fund0.08% weight · Holdings dated 30 June 2026
- VFMO · Vanguard U.S. Momentum Factor ETF0.07% weight · Holdings dated 15 September 2026
- BDSIX · BlackRock Advantage Small Cap Core Fund Institutional Shares0.06% weight · Holdings dated 29 May 2026
- FESM · Fidelity Enhanced Small Cap Core ETF0.05% weight · Holdings dated 30 June 2026
- PSOAX · JPMorgan Small Cap Value Fund Class A0.05% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.